Home / Business / European stocks and US stock futures rise on vaccine hopes and merger and acquisition stocks

European stocks and US stock futures rise on vaccine hopes and merger and acquisition stocks



Capped vials of Oxford University’s COVID-19 vaccine candidate, which restarted trials after a hiatus last week.

Vincenzo Pinto / Agence France-Presse / Getty Images

European equities marched higher on Monday, along with US stock futures, led by vaccine hopes, mergers and acquisitions news.

The Stoxx Europe 600 index
SXXP,
-0.04%

was up 0.3% after closing last week nearly 1.7% higher, the best weekly return since the week ending August 7
DAX,
-0.08%

gained 0.3%, the French CAC 40
PX1,
+ 0.11%

increased by 0.4%, while the FTSE 100 index
UKX,
-0.24%

he was trading plates.

Investors will be listening to the Federal Reserve, Bank of England, and Bank of Japan in the coming days in a busy week for central bank meetings.

Wall Street was also aiming for a stronger start, with Nasdaq-100 futures
NQ00,
+ 1.24%

up 145 points, or 1.3%, while S&P 500 futures
ES00,
+ 1.02%

were up 38.95 points, or 1.2%, and the Dow Jones Industrial Average futures
YM00,
+ 0.77%

jumped 278 points, or 1%.

These gains came in the wake of a losing week for Wall Street, with the Dow
DJIA,
+ 0.47%

down 1.7%, the S&P 500
SPX,
+ 0.05%

down 2.5% and the Nasdaq
COMP,
-0.60%

down 4.1%, the worst weekly loss since the week ending March 20.

Renewed hopes for a coronavirus vaccine also helped to improve sentiment earlier in the week.

Pfizer Inc.’s
PFE,
+ 1.17%

Chief Executive Albert Bourla said in an interview Sunday that the drug manufacturer should know if its COVID-19 vaccine candidate will work by the end of October and, if approved, could be released in the U.S. by the end of October. ‘year. Pfizer is partnering with German drug manufacturer BioNTech
BNTX,
+ 6.42%

on vaccine development.

Oxford University also announced on Saturday that it will resume a trial for the coronavirus candidate it is developing with AstraZeneca
AZN,
-0.60%
.
The study was stopped last week after a British patient fell ill pending a review of the “unexplained disease”. Oxford University said it was deemed safe to continue. AstraZeneca’s shares increased by 0.5%.

US-based Gilead Sciences Inc. announced on Sunday a $ 21 billion deal to purchase Biotech Immunomedics Inc. IMMU, a manufacturer of a key breast cancer drug.

Japanese tech conglomerate SoftBank Group Corp. announced late Sunday a $ 40 billion deal to sell UK-based microprocessor designer Arm Holdings to chip maker Nvidia
NVDA,
-1.19%

for a mix of cash and stocks.

The technology sector was also lifted by M&A, with shares in the German software group SAP SE
LYMPH,
-0.01%

up 0.3% and chip equipment manufacturer ASML Holding NV
ASML,
+ 0.62%

ASML,
+ 0.73%

up by 0.3%.

And the race for TikTok is heating up. Oracle Corp. software group
ORCL,
-0.57%

it was suggested to take over the video-sharing app in the US after China’s ByteDance apparently turned down an offer from tech giant Microsoft Corp.
MSFT,
-0.65%

But in the latest twist, Chinese state media claims ByteDance rejected Oracle as well.

Elsewhere, Euronext NV
ENX,
-3.98%

said on Monday that it had submitted a non-binding offer to acquire Borsa Italiana from London Stock Exchange Group PLC
LSE,
-1.28%
.
The pan-European exchange has collaborated with the Italian credit institutions Cassa Depositi e Prestiti Equity and Intesa Sanpaolo SpA
ISP,
-0.60%

on the offer. Shares of Euronext slid 0.2% and London Stock Exchange shares rose 0.5%.


Source link